Kisor DF - Search Results

1

Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.

Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin J, Krenitsky T, Elion G, Mitchell BS. Kurtzberg J, et al. Among authors: kisor df. J Clin Oncol. 2005 May 20;23(15):3396-403. doi: 10.1200/JCO.2005.03.199. J Clin Oncol. 2005. PMID: 15908652 Clinical Trial.

2

Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.

Gandhi V, Plunkett W, Rodriguez CO Jr, Nowak BJ, Du M, Ayres M, Kisor DF, Mitchell BS, Kurtzberg J, Keating MJ. Gandhi V, et al. Among authors: kisor df. J Clin Oncol. 1998 Nov;16(11):3607-15. doi: 10.1200/JCO.1998.16.11.3607. J Clin Oncol. 1998. PMID: 9817282 Clinical Trial.

3

Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies.

Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, Gandhi V. Kisor DF, et al. J Clin Oncol. 2000 Mar;18(5):995-1003. doi: 10.1200/JCO.2000.18.5.995. J Clin Oncol. 2000. PMID: 10694549 Clinical Trial.

4

Nelarabine: efficacy in the treatment of clinical malignancies.

Roecker AM, Allison JC, Kisor DF. Roecker AM, et al. Among authors: kisor df. Future Oncol. 2006 Aug;2(4):441-8. doi: 10.2217/14796694.2.4.441. Future Oncol. 2006. PMID: 16922610 Review.

5

Nelarabine in the treatment of refractory T-cell malignancies.

Roecker AM, Stockert A, Kisor DF. Roecker AM, et al. Among authors: kisor df. Clin Med Insights Oncol. 2010 Dec 1;4:133-41. doi: 10.4137/CMO.S4364. Clin Med Insights Oncol. 2010. PMID: 21151585 Free PMC article.

6

Nelarabine use in leukemias.

Kisor DF. Kisor DF. Drugs Today (Barc). 2006 Jul;42(7):455-65. doi: 10.1358/dot.2006.42.7.985638. Drugs Today (Barc). 2006. PMID: 16894400 Review.

7

Pharmacokinetics of RheothRx injection in healthy male volunteers.

Jewell RC, Khor SP, Kisor DF, LaCroix KA, Wargin WA. Jewell RC, et al. Among authors: kisor df. J Pharm Sci. 1997 Jul;86(7):808-12. doi: 10.1021/js960491e. J Pharm Sci. 1997. PMID: 9232521 Clinical Trial.

8

Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias.

Kisor DF. Kisor DF. Ann Pharmacother. 2005 Jun;39(6):1056-63. doi: 10.1345/aph.1E453. Epub 2005 May 3. Ann Pharmacother. 2005. PMID: 15870141 Review.

9

Clinical pharmacokinetics of cisatracurium besilate.

Kisor DF, Schmith VD. Kisor DF, et al. Clin Pharmacokinet. 1999 Jan;36(1):27-40. doi: 10.2165/00003088-199936010-00003. Clin Pharmacokinet. 1999. PMID: 9989341 Review.

10

Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.

Reilly KM, Kisor DF. Reilly KM, et al. Among authors: kisor df. Onco Targets Ther. 2009 Feb 18;2:219-28. doi: 10.2147/ott.s4770. Onco Targets Ther. 2009. PMID: 20616909 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters